drugset / Trial / NCT00238355
Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems
Phase 2
Terminated
13 enrolled
OHSU Knight Cancer Institute
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelSupportive care
Summary
RATIONALE: Voriconazole and caspofungin acetate may control invasive fungal infections in patients who have weakened immune systems. PURPOSE: This phase II trial is studying how well giving voriconazole together with caspofungin acetate works in treating invasive fungal infections in patients with weakened immune systems.
Timeline
- Start
- 2003-08
- Primary completion
- 2008-06
- Completion
- 2008-06
Outcome
Outcome not reported
Stopped: “competing study at site”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Caspofungin | Other / unclassified | 50 mg | Intravenous |
| Subject | Voriconazole | Small molecule | 4 mg/kg | Intravenous |
| Subject | Voriconazole | Small molecule | 200 mg | Intravenous |